Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
TXG

Price
18.62
Stock movement up
+0.51 (2.25%)
Company name
10X Genomics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Health Information Services
Market cap
2.70B
Ent value
2.51B
Price/Sales
4.21
Price/Book
3.44
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
13.66%
1 year return (CAGR)
43.50%
3 year return (CAGR)
-18.83%
5 year return (CAGR)
-33.62%
10 year return (CAGR)
-
Last updated: 2026-02-12

iO Charts is a Seeking Alpha partner

DIVIDENDS

TXG does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF30.51
Price to FCF33.08
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.21
Price to Book3.44
EV to Sales3.91

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count116.47M
EPS (TTM)-0.34
FCF per share (TTM)1.02

Income statement

Loading...
Income statement data
Revenue (TTM)642.82M
Gross profit (TTM)443.88M
Operating income (TTM)-60.98M
Net income (TTM)-43.54M
EPS (TTM)-0.34
EPS (1y forward)0.16

Margins

Loading...
Margins data
Gross margin (TTM)69.05%
Operating margin (TTM)-9.49%
Profit margin (TTM)-6.77%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash473.97M
Net receivables82.49M
Total current assets684.45M
Goodwill4.51M
Intangible assets62.33M
Property, plant and equipment440.63M
Total assets1.04B
Accounts payable12.73M
Short/Current long term debt157.74M
Total current liabilities153.45M
Total liabilities245.04M
Shareholder's equity796.33M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)136.05M
Capital expenditures (TTM)5.93M
Free cash flow (TTM)130.12M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-5.47%
Return on Assets-4.18%
Return on Invested Capital-5.39%
Cash Return on Invested Capital16.12%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open22.90
Daily high23.53
Daily low22.56
Daily Volume2.70M
All-time high202.37
1y analyst estimate20.14
Beta2.21
EPS (TTM)-0.34
Dividend per share0.00
Ex-div date-
Next earnings date6 May 2026

Downside potential

Loading...
Downside potential data
TXGS&P500
Current price drop from All-time high-90.80%-1.82%
Highest price drop-96.47%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-57.77%-10.84%
Avg time to new high30 days12 days
Max time to new high1192 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
TXG (10X Genomics Inc) company logo
Marketcap
2.70B
Marketcap category
Mid-cap
Description
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Employees
1178
Investor relations
-
SEC filings
CEO
Serge Saxonov
Country
USA
City
Pleasanton
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...